This article aims to critically review the evidence on the available therapeutic strategies for
the treatment of hyperuricemia. For this reason, several papers were reviewed. Xanthine …

This review aims to critically present the available clinical evidence supporting the treatment
of chronic hyperuricemia with xanthine oxidase inhibitors. For this reason, the studies …

Rationale & Objective Hyperuricemia has been implicated in the development and
progression of chronic kidney disease. Verinurad is a novel, potent, specific urate …

Introduction: The significant proportion of gout patients not reaching serum urate levels
below 6.0 mg/dL and the debated pathogenicity of hyperuricemia (HU) itself motivate …

Lesinurad, a human urate transporter 1 (URAT1) inhibitor approved as a medication for the
treatment of hyperuricemia associated with gout in 2015, can cause liver and renal toxicity …

Introduction Inflammation induced by urate deposition in joints causes gout. Healthy
individuals maintain serum levels of urate by balancing urate production/excretion, whereas …

Hyperuricemia is a common metabolic condition, cause by increased levels of serum urate
(SUA). Reduced excretion of uric acid is reported as the key factor of primary hyperuricemia …

Fraxini Cortex (also known as Qinpi, QP) has been used for the treatment of hyperuricemia
with a significant difference on efficacy of QP from different regions. However, its still …

Objective: Evaluate efficacy/safety of verinurad monotherapy in patients with gout
(Japan/US) or asymptomatic hyperuricemia (Japan). Methods: Two randomized, placebo …

Hyperuricemia with consequent monosodium urate crystal deposition leads to gout,
characterized by painful, incapacitating inflammatory arthritis flares that are also associated …